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Abstract 
Purpose: To evaluate the anticancer activity of an enzyme, methioninase, obtained from a soil isolate, 
Serratia marcesens, against Dalton’s lymphoma ascitic (DLA) and Ehrlich ascitic carcinoma (EAC) in Swiss 
albino mice. 
Methods: Cancer was induced using DLA and EAC cells in Swiss albino mice by intraperitoneal injection. 
The mice were then treated with 10 and 20 mg/kg body weight of methioninase; 5-fluorouracil (5-FU) was 
used as standard. 
Results: The results showed good improvement in haematological parameters, improvement serum 
enzymes and lipid profile, as well as increase in life span by up to 77 %, increase in body weight (p < 0.01), 
decrease in cancer cell count from (2.70 ± 0.40) × 106 to (1.86 ± 0.30) × 106 cells/ml compared to (2.70 ± 
0.40) × 106 to (1.42 ± 0.25) x 106 cells/ml for the group treated with 5-FU. Solid tumor volume decreased from 
5.82 ± 0.15 to 4.10 ± 0.11 ml as as against a decrease from 5.82 ± 0.40 to 3.56 ± 0.28 for the group treated 
with 5-FU. 
Conclusion: The isolated enzyme, methioninase, has a good anti-cancer activity and needs to be further be 
investigated for this activity.  
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Cancer is a disease characterized by abnormal 
proliferation of cells. It is one of the leading 
causes of death in the world, and it is of serious 
to people living in both the developing and 
developed nations [1]. Both benign and 
malignant tumors manifest as uncontrolled 
proliferation, but the latter are distinguished by 
their capacity to dedifferentiate, their 
invasiveness and their ability to metastasise. 
Cancer can be cured without much problem if it 
is diagnosed at the earlier stages. The 
treatments include chemotherapy, radiation and 
other forms of therapy. Every therapy has its own 
advantages and disadvantages.  
 
Nutritional starvation of cancer cells have been 
tried by many researchers and have been found 
to be successful in a few cases. Cancer cells 
have absolute requirements for nutrition, a few of 
its nutrients it can synthesize and for a few 
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others it depends on the host cell. Amino acids 
like methionine and asparagine come under 
these categories [2,3]. If the cancer cells are 
deprived of these amino acids, they starve to 
death, since they can’t synthesize these amino 
acids [4]. Nutritional starvation can be done by 
two ways, one by controlling the dietary intake of 
these amino acids and the other by decreasing 
the serum concentration of these amino acids.  
 
Previous literatures have shown that dietary 
methionine starvation extended the life span of 
tumor bearing animals and lowered the 
metastatic rate of the methionine dependent 
tumor. However, dietary methionine starvation is 
insufficient to completely arrest tumor growth. 
Depleting serum concentration can be done by 
the administration of the enzyme, methioninase, 
which can cleave methionine to α – ketobutyrate, 
methanethiol and ammonia [5]. In our study, we 
have isolated a bacterium from soil which has the 
capability of producing methioninase and this 
enzyme was purified. The objective of the study 
was to evaluate the anti tumor activity of 
methioninase against Daltons Lymphoma Ascitic 





For the study of anticancer activity, an 
experimental model was selected in such that it 
would satisfy the following conditions such as: 
the animal should develop cancer rapidly and 
reproducibly, pathological changes in the site of 
induction should result from cancer formation, 
the symptoms should be ameliorated or 
prevented by a drug treatment effective in human 
beings, the drug tested should be administered 
orally and drug dosage should approximate the 
optimum therapeutic range for humans, when the 
dose is scaled with respect to the test animal 
weight. The study was carried out after obtaining 
permission from the Institutional Animal Ethical 
Committee (Reg No: 661/02/c/CPCSEA, 
approval ref no. A.S. William/200801212/KU/ 
IAEC/KMCP/43/2013) and OECD guidelines 451 
were adhered to in the study [6].   
 
Selection, grouping and acclimatization of 
laboratory animal  
 
Male Swiss albino mice (weighing 20 - 25 g 
each) were procured from the animal 
experimentation laboratory of K.M. College of 
Pharmacy, Madurai, India and used throughout 
the study. They were housed in micro nylon 
boxes in a controlled environment (25 ± 2 0C) 
and 12 h/12 h dark/light cycle with standard 
laboratory diet and water ad libitum [7]. The 
study was conducted after obtaining institutional 
animal ethical committee clearance. As per the 
standard practice, the mice were segregated 
based on their gender and quarantined for 15 
days before commencement of the experiment. 
They were maintained in a hygienic environment 
in the animal house. 
 
Induction of tumor 
 
Various techniques for induction of cancer in 
animals, viz, chemically-induced (using 
DMBA/croton oil, etc) [8], virus-induced, cell-
induced (sarcoma – 180, ULCA fibro sarcoma 
and Jensen sarcoma, mouse lung fibroblast cells 
L-929, DLA and EAC) [9-11] methods have been 
used in various experimental studies of 
anticancer activity. In the present study, cell lines 
were used to induce cancer in mice and used to 
evaluate anticancer activity. 
 
Dalton’s lymphoma ascitic (DLA) and Ehrlich 
ascitic carcinoma (EAC) cells were procured 
from Amla Cancer Research Center, Trissur, 
Kerala, India. The cells were maintained in vivo 
in Swiss albino mice by intraperitonial 
transplantation. While transforming the tumor 
cells to the grouped animals, the DLA cells and 
EAC cells were aspirated from the peritoneal 
cavity of the mice using saline with a no: 26 
gauge needle attached to a 1 ml syringe. The cell 
counts were noted and further dilutions were 
made so that the total cells were 1 x 106, and 
given intraperitonially. The tumor was allowed to 
grow in the mice for a minimum of seven days 
before commencing the study.  
 
Treatment protocol for Dalton’s lymphoma 
ascitic (DLA) cells 
 
Swiss albino mice were divided into four groups 
of six animals each (Table 1). All the animals in 
the three groups were injected with Dalton’s 
lymphoma ascitic (DLA) cells (1 x 106 
cells/ml/mouse), intraperitoneally, and the 
remaining group was normal control. 
 
Table 1: Grouping of animals 
 
S/N Group Name 
1 I Normal control 
2 II Tumor control 
3 III  control group, treated with 5-
flourouracil at 20 mg/kg body weight, 
i.p. [12] 
4 IV Treatment control, administered 
methioninase in a dose of 10 mg/kg 
body weight, i.p. 
5 IV Treatment group, administered 
methioninase in a dose of 20 mg/kg 
body weight, i.p. 
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In this study, drug treatment was given after 24 h 
of inoculation, once daily for 14 days. After the 
last dose was given on the 14th day, all mice from 
each group were sacrificed by euthanasia. Blood 
was withdrawn from each mouse by retro orbital 
puncture technique and hematological 
parameters, namely, WBC count, RBC count, 
haemoglobin content, platelet count and packed 
cell volume were determined. Serum enzyme 
and lipid profiles were assessed to determine 
total cholesterol, triglyceride, alanine amino 
transferase, alkaline phosphatase, and aspartate 
amino transferase. All the biochemical 
investigations were done by using COBAS MIRA 
PLUS – S autoanalyser (Roche, Switzerland) 
while haematological parameters were obtained 
using COBAS MICROS OT 18 (Roche, 
Switzerland). The animals were also monitored 
for these parameters as well as for other 
parameters - body weight, life span and cancer 
cell count.  
 
Cancer cell count  
 
The fluid (0.1 ml) from the peritoneal cavity of 
each mouse was withdrawn with sterile syringe 
and diluted with 0.8 ml of sterile phosphate buffer 
solution or ice cold normal saline and 0.1 ml of 
tryphan blue (0.1 mg/ml) and the total number of 
viable cells were counted using haemocytometer 
by trypan blue dye exclusion method [13]. 
 
Treatment protocol for Ehrlich ascitic 
carcinoma (EAC) cells 
 
Swiss albino mice were divided into three groups 
(n = 6). Tumor cells (1 x 106 cells/mouse) were 
injected into the right limb (thigh) of all the 
animals intramuscularly except one group which 
served as control. The mice in Group I were 
tumor control, Group II was control treated with 
5-FU at 20 mg/kg body weight. Groups III and IV 
received methioninase [14] at a dose of 10 and 
20 mg/kg orally on 5 alternative days. Tumor 
mass was measured from the 11th day of tumor 
induction. The diameter of the tumor was 
measured on every 5th day for a period of 30 
days using Vernier callipers and the volume of 
the tumor mass was calculated using the formula 
V = 4/3πr2, where r is the mean of r1 and r2, 





The results were expressed as mean ± standard 
error of the mean (SEM). Statistical significance 
was assessed using one-way analysis of 
variance (ANOVA) followed by Newmann Keul’s 
multiple range test; p < 0.05 was taken as the 




Effect of L. methioninase on the haema-
tological parameters: of mice with DLA cells 
 
The results of the haematological studies are 
shown in Table 2. RBC content, haemoglobin 
level and platelet counts lower while WBC count 
significantly was higher in the DLA control group 
than in the normal control group. Treatment with 
methioninase at a dose of 10 and 20 mg/kg 
significantly increased haemoglobin content (p < 
0.01) from 7.32±0.92 to 10.60 ± 1.32 and 10.30 ± 
0.98, respectively, compared to 11.80 ± 1.56 for 
5-FU control group. The RBC content was 
increased significantly (p < 0.01) from 2.44 ± 
0.50 in DLA control to 3.34 ± 0.70 and 3.10 ± 
0.52 in mice-treated at methioninase doses of 10 
and 20 mg/kg as compared to 4.16 ± 0.90 for 5-
FU standard control. Platelet count rose 
significantly (p < 0.01) from 1.72 ± 0.62 for DLA 
control to 2.12 ± 0.80 and 2.30 ± 0.92 in mice 
treated with methioninase at 10 and 20 mg/kg 
doses compared to 2.80 ± 0.90 for 5-FU 
standard group. A  significant reduction in WBC 
count (p < 0.01) from 14.08 ± 2.40 for DLA 
control to 12.60 ± 1.96 and 12.15 ± 1.55 in mice 
treated with methioninase at 10 and 20 mg/kg 
doses compared to 11.35 ± 1.85 for 5-FU 
standard. These results suggest that 
methioninase exerts good anticancer activity 
against DLA, although it was not as strong as 
that of the standard, 5-FU, at a dose of 20 mg/kg.  
 
Effect of L-methioninase on biochemical 
parameters 
 
The inoculation of DLA cells caused a significant 
increase (p-value) in the level of total cholesterol, 
triglycerides, aspartate amino transferase, 
alkaline phosphatase and alanine amino 
transferase in the tumor control animals (G2), 
when compared to the normal group. Treatment 
with methioninase from soil at doses of 10 and 
20 mg/kg reversed these changes to normal 
levels as can be seen in Table 3. These changes 
were all significant (p < 0.01) when compared 
with normal or treatment control. Treatment with 
5-FU also produced a similar result. 
 
Effect of L-methioninase on DLA-induced 
tumor 
 
In the DLA tumor group, the average life span of 
the animal was 50 % for cancer control animals 
whereas methioninase-treated animals at doses 
of 10 and 20 mg/kg showed increase in life span 
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to 72 and 77 %, respectively (Table 4). The anti-
tumor activity of methioninase was also evident 
in the significant reduction in the increase in 
viable tumor cell count (P<0.01) and packed cell 
volume, (P<0.01) when compared with normal 
control. 
 
Effect of methioninase on EAC-induced solid 
tumor 
 
The solid tumor volume induced by EAC cells 
significantly increased from day 0 to 30 as can 
be seen in Table 5. However, tumor volume 
significantly decreased in animals treated with 
methioninase from day 15 to the end of the 
experiment. Approximately 27 and 30 % 
reduction in tumor volume was observed with 10 
and 20 mg/kg of methioninase doses, 




The emergence of drug resistance and adverse 
effects of available chemotherapeutic agents 
always necessitates discovery and development 
of new drugs, targeting new roles and models. 
Many cancer cells have an absolute requirement 
for plasma methionine, whereas normal cells are  
 




(cells x10 3/ml) 
RBC count 





Normal control 10.46 ±1.58 4.50±0.96 12.44 ±1.30 3.45±0.90 
Cancer control 14.08 ±2.40a** 2.44±0.50a** 7.32  ±0.92a** 1.72±0.62a** 
5-FU (20mg/kg) 11.35 ±1.85b** 4.16±0.90b** 11.8 ±1.56b** 2.80±0.90b** 
Methioninase  (10 mg/kg) 12.60 ±1.96b** 3.34±0.70b** 10.60±1.32b** 2.12 ±0.80b** 
Methioninase (20 mg/kg) 12.15±1.55b** 3.10±0.52b** 10.30±0.98b** 2.30±0.92b** 
**a – significantly different from control (G1) at p < 0.01; **b – significantly different from cancer control (G2) at p < 0.01 
 












Normal control 113.30±3.70 134.90±2.52 42.65±1.32 34.50±1.60 127.40±2.45 
Cancer control 147.9±4.65a** 224.40±4.82 a** 87.4±2.90 a** 63.22±2.70 a** 240.32±4.21 a**
5-FU (20mg/kg) 124.50±3.85 b** 164.65±2.42 b** 57.42±1.83 b** 44.35±1.75 b** 160.30±2.43 b**
Methioninase  (10 mg/kg) 122.50±3.60 b** 176.70±2.65 b** 67.45±1.92 b** 47.35± 1.90 b** 192.78±2.70 b**
Methioninase (20 mg/kg) 120.34±3.53 b** 171.82±2.55 b** 62.55±2.32 b** 46.30±1.72 b** 190.43±2.32 b**±
**a – significantly different from control (G1) at p < 0.01; **b – significantly different from cancer control (G2) at p < 0.01 
  
Table 4:  Effect of methioninase on the life span, body weight and cancer cell count of tumor-induced 
mice (n = 6) 
 
Treatment % ILS/life span Increase in body 
weight (g) 
Cancer cell count 
 x 106 cells/ml 
PCV 
(%) 
Normal control >> 30 days   2.30±0.62 - 14.30±2.45 
Cancer control 50% 7.80±0.95a** 2.70±0.40a** 30.40±3.26 a** 
5-FU (20mg/kg) 90% 3.75±0.70b** 1.42±0.25b** 18.26±1.50 b** 
Methioninase (10 mg/kg) 72% 4.18±0.70b** 1.86±0.36b** 22.40±1.55 b** 
Methioninase (20 mg/kg) 77% 4.30±0.80b** 1.76±0.30b** 24.35±2.45 b** 
**a = significantly different from control (G1) at p < 0.01; **b = significantly different from cancer control (G2) at p < 0.01 
Table 5:  Effect of methioninase on solid tumor volume (n=6) in EAC tumor-bearing mice 
 
Solid tumor volume Treatment  Dose 
15th day 20th day 25th day 30th day 
Cancer control 2 ml/kg saline 2.63±0.14 3.59±0.15 4.72±0.15 5.82±0.15 
Standard control (5-FU) 20 mg/kg 2.54±0.15 3.25±0.22 3.40±0.24 3.56±0.28 
Treatment group 10 mg/kg methioninase 2.42±0.15 3.36±0.23 3.61±0.19 4.24±0.17**a
Treatment group 20 mg/kg methioninase 2.66±0.16 3.36±0.17 3.37±0.17 4.10±0.11**a
**a = significantly different from tumor control (G1) at p < 0.01 
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relatively resistant to the restriction of exogenous 
methionine. This can be achieved by the 
administration of methioninase, an enzyme which 
cleaves the dietary methionine.  Methionine 
depletion has broad spectrum of antitumor 
activity. 
 
In the present study, we have induced cancer by 
using DLA and EAC cell lines. The cancer-
induced mice were treated with methioninase at 
doses of 10 and 20 mg/kg. In DLA tumor-bearing 
animals, a rapid increase in the ascitic tumor 
volume was observed. Ascitic fluid is a direct 
nutritional source for tumor cells and therefore a 
rapid increase in ascitic fluid with tumor growth 
would be a means to meet the nutritional 
requirement of the tumor cells. Treatment with 
methioninase inhibited viable tumor cell count, 
solid tumor volume and increased the life span of 
the tumor bearing mice possibly by causing 
nutrition starvation for the enzyme methionine.  
 
The criteria for judging the value of any 
anticancer drug is the prolongation of the life 
span of animals. It may be concluded that 
methioninase, by decreasing the nutritional fluid 
volume and arresting tumor growth, increases 
the life span of DLA bearing mice. There was 
also a reduction in solid tumor volume of EAC 
bearing mice indicating that methioninase is 
involved in the reduction of tumor. Usually in 
cancer chemotherapy, the major problems that 
are encountered are myleo-suppression and 
anaemia [15,16]. The anaemia encountered in 
tumor-bearing mice is mainly due to reduction in 
RBC or haemoglobin and this may occur either 
due to iron deficiency or to haemolytic or 
myleopathic conditions. Treatment with 
methioninase restored haemoglobin content, 
RBC and WBC count to more or less normal 
levels. This indicates that methioninase has 
protective effect on the hematopoietic system. 
 
It has been reported that the presence of tumor 
in human body or in experimental animals is 
known to affect many functions of the liver [17]. 
The significantly elevated levels of total 
cholesterol, triglycerides, aspartate amino 
transferase, alkaline phosphatase, alanine amino 
transferase in the serum of tumor inoculated 
animals indicate liver damage and loss of 
functional integrity of cell membrane.  In the 
present study, the marked biochemical changes 
in DLA inoculated animals indicate the toxic 
effect produce in the animals by the tumor. The 
normalization of these effects observed in the 
serum of animals treated with methioninase 
supports the potent anti tumor and 
hepatoprotective effects of methioninase isolated 
from soil. 
The significant reduction in the volume of solid 
tumor shows that the methioninase exerts a 
potent cytotoxic activity against solid tumors.  
Where there is methionine depletion, cancer cells 
are arrested in the late S-G2 phase due to 
pleiotropic effect and they undergo apoptosis. 
From the above results it can be found that 
methioninase isolated from soil bacterium shows 





The isolated enzyme methioninase has been 
found to possess significant antitumor activity 
and increased life span of tumor bearing mice. 
Further investigations are in progress in our 
laboratory to optimize the medium composition 
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